Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech Center experience

Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

WEINBERGEROVÁ Barbora ČERŇAN Martin KABUT Tomáš SEMERÁD Lukáš PODSTAVKOVÁ Natália SZOTKOWSKI Tomáš JEŽÍŠKOVÁ Ivana MAYER Jiří

Year of publication 2023
Type Article in Periodical
Magazine / Source Haematologica
MU Faculty or unit

Faculty of Medicine

Citation
Web https://haematologica.org/article/view/haematol.2022.282263
Doi http://dx.doi.org/10.3324/haematol.2022.282263
Keywords Gemtuzumab ozogamicin; midostaurin; acute myeloid leukemia
Attached files
Description For more than four decades, conventional therapy for acute myeloid leukemia (AML) has been represented by cytarabine/anthracycline-containing regimens, followed by consolidation therapy, including allogeneic hematopoietic stem cell transplantation (allo-HSCT). In recent years, approach to the treatment of AML has significantly shifted toward the use of novel and effective, target-directed therapies, including anti-CD33 immunoconjugate, gemtuzumab ozogamicin (GO), and inhibitor of mutant FMS-like tyrosine kinase 3 (FLT3), midostaurin (MIDO).
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info